UPDATE : Monday, September 7, 2020
상단여백
HOME Pharma
Lilly returns rights for Hanmi’s BTK inhibitor candidate
  • By Lee Han-soo
  • Published 2019.01.23 10:21
  • Updated 2019.01.23 10:21
  • comments 0

Hanmi Pharmaceutical said Wednesday that Lilly has returned licensing rights for LY3337641/HM71224, a Bruton's tyrosine kinase (BTK) inhibitor. “Lilly’s decision came after a comprehensive review of all clinical data and the BTK inhibitor market,” a Hanmi official said.

Lilly decided to discontinue the phase-2 trials of selective BTK inhibitor LY3337641/HM71224 in patients with rheumatoid arthritis because interim results showed that the study could fail to demonstrate its target effectiveness in January last year.

At the time, Lilly stressed that it would not terminate the contract with Hanmi and search for new indications instead. Despite the return of rights, Hanmi will not have to return the $53 million initial contract fee it received from Lilly.

Hanmi plans to receive all clinical and developmental data from Lilly within 90 days of returning the BTK inhibitor right, and intends to proceed independently to develop other indications for the drug.

However, the return of rights for its BTK inhibitor candidate pulled down the company’s stocks. Hanmi Pharmaceutical shares stood at 436,000 won ($385) at 10:00 a.m. Wednesday, down 2.57 percent from the previous trading day.

corea022@docdocdoc.co.kr

<© Korea Biomedical Review, All rights reserved.>

Other articles by Lee Han-soo
iconMost viewed
Comments 0
More
Please leave the first comment.
여백
여백
여백
Back to Top